~ Leading Experts Presenting New Clinical Approaches to Treat Severe Pain at PAINWeek Symposium ~
SAN DIEGO, CA / ACCESSWIRE / September 7, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is presenting clinical data at PAINWeek, the leading US pain conference, today, September 7, 2023, in Las Vegas, NV.
America remains gripped by the opioid epidemic and this is creating another looming crisis: patients deprived of access to medication for severe pain. Ensysce is working to address both crises by developing unique and safer opioid products. Today the Company is presenting their groundbreaking approaches at PAINWeek 2023.
This scientific session will explore the latest information on severe pain treatment, the ongoing issues with current products on the market, and examine the safety and effectiveness of two ‘Next-Generation analgesics' from Ensysce Biosciences, PF614 and PF614-MPAR. The faculty is comprised of world experts in the field, featuring Dr. Jeff Gudin, a Pain Physician at the University of Miami.
The data being presented builds a picture of unique safety combined with powerful pain relief, charting the progress of these drugs in development from animal models to compelling human clinical data. The latest data being presented will highlight the Ensysce approach to reduce prescription drug overdoses, an approach that could herald a first for the industry.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are at a precipice in America where we are now dealing with dueling crises: pain versus drug abuse and overdose. The issue of opioid abuse has led to major problems for some people who live in chronic severe pain and who need an opioid medication. Many have found reduced access to their life-changing medication due to the restrictions that have been put on opioid prescribing. Ensysce is re-engineering opioids, building in features which we believe will make them a safer product to prescribe and with added potential for overdose protection. We hope that our products can provide novel options for both physicians and patients."
Dr. Gudin commented, "There are few true innovations in the treatment of severe pain. I see the Ensysce approach as a potential game changer when opioids are needed for the treatment of pain. Clinicians need treatment options, and patients in severe pain need the best and safest approaches available. I support any new products that provide effective analgesia with added safety features and especially overdose protection."
PAINWeek is the leading US pain conference with the most expansive curriculum for frontline practitioners to enhance their competence in pain management. Please find more information here.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company applying transformative chemistry to improve prescription drug safety. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing ‘Next Generation' analgesics for moderate to severe pain. Ensysce's products are anticipated to provide safer options for patients and assist in preventing medication overdose. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
Ensysce Biosciences Investor Relations Contact:
MZ North America
SOURCE: Ensysce Biosciences Inc.
View source version on accesswire.com: